The understanding of NSCLC pathogenesis has improved through the identification of activating mutations in and amplifications of oncogenes, including KRAS [24], EGFR [25], KARS [26], and inactivating mutations in tumor suppressive genes, such as p53 [27, 28]. This evidence concerns the gene EGFR and neoplasm.